Eton Pharmaceutical
ETON
54.88
+0.11
+0.20%
Eton Pharmaceutical
US · ETON
#2944 by market cap
Listed 2018
54.88
+0.11
+0.20%
Live - 5344 symbols - heartbeat 364s ago
· 2026-10-08 08:16
Pre-market
54.60
-0.51%
After-hours
55.10
+0.40%
- Market cap
- 1.57B
- P/E (TTM)i
- 140.72
- P/Bi
- 33.67
- EPSi
- -0.17
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on ETON?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 13.68, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +104.94% YoY
Margins
- Gross margin
- 53.46%
- Operating margin
- -1.06%
- Net margin
- -5.75%
Key ratios & quality
- Enterprise valuei
- 1.57B
- Altman Z-Scorei
- 13.68
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 959.00K | 39.00K | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Gross profit | 0 | 506.00K | -397.00K | 19.01M | 14.32M | 21.06M | 23.41M | 42.74M |
| Selling & admin expenses | 4.69M | 7.55M | 12.61M | 14.27M | 18.58M | 18.93M | 22.75M | 35.82M |
| Research & development | 5.63M | 11.56M | 14.10M | 6.24M | 4.00M | 3.32M | 3.26M | 7.77M |
| Operating profit | -10.32M | -18.60M | -27.11M | -1.50M | -8.26M | -1.19M | -2.60M | -844.00K |
| Pretax profit | -12.74M | -18.32M | -27.97M | -1.96M | -9.02M | -689.00K | -3.81M | -4.56M |
| Tax | 0 | 0 | 0 | 0 | 0 | 247.00K | 15.00K | 43.00K |
| Net profit | -12.74M | -18.32M | -27.97M | -1.96M | -9.02M | -936.00K | -3.82M | -4.60M |
| Basic EPS | -6 | -1 | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -5.80 | -1.03 | -1.33 | -0.08 | -0.36 | -0.04 | -0.15 | -0.17 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 17.28M | 18.93M | 22.46M | 21.28M | 24.27M | 37.59M |
| Gross profit | 9.86M | 11.92M | 7.86M | 13.10M | 14.74M | 25.41M |
| Selling & admin expenses | 9.17M | 9.69M | 8.11M | 8.86M | 10.45M | 11.63M |
| Research & development | 1.16M | 3.71M | 1.11M | 1.78M | 1.88M | 993.00K |
| Operating profit | -470.00K | -1.48M | -1.36M | 2.46M | 2.41M | 12.79M |
| Pretax profit | -1.50M | -2.52M | -1.96M | 1.41M | 1.57M | 11.72M |
| Tax | 74.00K | 66.00K | -28.00K | -69.00K | 20.00K | 140.00K |
| Net profit | -1.57M | -2.59M | -1.93M | 1.48M | 1.55M | 11.58M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.06 | -0.10 | -0.07 | 0.05 | 0.05 | 0.35 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 27.50M | 15.01M | 24.70M | 23.60M | 20.00M | 26.84M | 41.02M | 60.58M |
| Cash & ST investments | 26.74M | 12.07M | 21.30M | 14.41M | 16.31M | 21.39M | 14.94M | 25.94M |
| Inventory | 0 | 380.00K | 1.24M | 550.00K | 557.00K | 911.00K | 15.23M | 15.42M |
| Total assets | 28.33M | 17.07M | 26.32M | 27.47M | 25.03M | 31.74M | 76.12M | 92.11M |
| Total current liabilities | 2.02M | 1.96M | 3.79M | 4.56M | 6.46M | 16.24M | 19.95M | 38.49M |
| Short-term debt | -- | -- | 280.00K | 1.42M | 1.03M | 5.38M | -- | 8.79M |
| Long-term debt | -- | 4.54M | 6.76M | 5.26M | 5.38M | -- | 29.81M | 21.77M |
| Total liabilities | 2,024,000.00 | 6,522,000.00 | 10,656,000.00 | 9,835,000.00 | 11,952,000.00 | 16,263,000.00 | 51,695,000.00 | 65,960,000.00 |
| Total equity | 26.30M | 10.55M | 15.66M | 17.63M | 13.08M | 15.48M | 24.43M | 26.15M |
| Retained earnings | -45.87M | -64.19M | -92.16M | -94.11M | -103.13M | -104.07M | -107.89M | -112.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 49.96M | 68.44M | 72.00M | 60.58M | 53.25M | 68.60M |
| Cash & ST investments | 17.42M | 25.38M | 37.12M | 25.94M | 19.66M | 26.85M |
| Inventory | 13.62M | 23.79M | 16.86M | 15.42M | 14.47M | 10.14M |
| Total assets | 84.03M | 101.68M | 104.51M | 92.11M | 97.71M | 115.81M |
| Total current liabilities | 25.35M | 38.60M | 44.18M | 38.49M | 44.18M | 45.12M |
| Short-term debt | -- | 2.77M | 2.78M | 8.79M | 11.81M | 8.83M |
| Long-term debt | 29.99M | 27.41M | 27.59M | 21.77M | 18.94M | 19.08M |
| Total liabilities | 59,582,000.00 | 77,715,000.00 | 81,384,000.00 | 65,960,000.00 | 67,095,000.00 | 69,222,000.00 |
| Total equity | 24.45M | 23.96M | 23.13M | 26.15M | 30.62M | 46.59M |
| Retained earnings | -109.47M | -112.05M | -113.98M | -112.49M | -110.94M | -99.36M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.15M | -18.03M | -22.35M | -4.72M | 4.82M | 6.82M | 969.00K | 10.52M |
| Depreciation & amortization | 63.00K | 447.00K | 651.00K | 462.00K | 1.77M | 901.00K | 1.15M | 4.04M |
| Free cash flow | -8.38M | -19.87M | -22.40M | -7.98M | 2.03M | 6.04M | -9.05M | 10.19M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 22.80M | 0 | 28.78M | -- | 0 | 0 | 7.00M | 0 |
| Ending cash balance | 26.74M | 12.07M | 21.30M | 14.41M | 16.31M | 21.39M | 14.94M | 25.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.09M | 7.96M | 12.03M | -11.55M | 7.41M | 7.26M |
| Depreciation & amortization | 1.01M | 1.01M | 1.01M | 1.02M | 1.13M | 1.39M |
| Free cash flow | 2.09M | 7.96M | 11.74M | -11.60M | -7.67M | 7.26M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 17.42M | 25.38M | 37.12M | 25.94M | 19.66M | 26.85M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -383.23 | -99.42 | -213.41 | -11.74 | -58.75 | -6.56 | -19.16 | -18.19 |
| ROA %i | -178.26 | -80.71 | -128.92 | -7.27 | -34.37 | -3.30 | -7.09 | -5.47 |
| ROIC %i | -383.23 | -79.70 | -146.46 | -8.30 | -41.07 | -4.62 | -10.95 | -7.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -153.31 | -77.98 | -61.92 | -22.88 |
| EBIT margin %i | -- | -1,939.62 | -69,515.38 | -6.85 | -38.87 | -3.77 | -6.66 | -1.06 |
| FCF / sales %i | -- | -- | -- | -- | 9.57 | 19.09 | -- | 12.75 |
| Current ratioi | 13.59 | 7.65 | 6.51 | 5.18 | 3.10 | 1.65 | 2.06 | 1.57 |
| Quick ratioi | 13.21 | 6.39 | 5.63 | 4.36 | 2.81 | 1.53 | 1.02 | 0.98 |
| Debt / assetsi | 0.00 | 26.70 | 27.14 | 24.38 | 26.06 | 17.02 | 39.30 | 33.67 |
| LT debt / equityi | -- | 43.21 | 43.81 | 29.93 | 41.99 | 0.14 | 122.47 | 84.99 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 180.88 | 832.68 | 21.35 | 55.53 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 71.14 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -22.95 | -22.06 | -34.17 | -18.19 | -5.36 | 35.97 |
| ROA %i | -7.98 | -6.18 | -9.52 | -5.47 | -1.62 | 11.67 |
| ROIC %i | -13.09 | -11.33 | -18.01 | -7.65 | -2.30 | 19.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.69 | -1.39 | -3.81 | -1.06 | 2.35 | 15.44 |
| FCF / sales %i | -- | 7.05 | 18.34 | 12.75 | 0.50 | -- |
| Current ratioi | 1.97 | 1.77 | 1.63 | 1.57 | 1.21 | 1.52 |
| Quick ratioi | 1.33 | 1.03 | 1.14 | 0.98 | 0.75 | 1.15 |
| Debt / assetsi | 35.79 | 30.16 | 29.52 | 33.67 | 31.92 | 25.03 |
| LT debt / equityi | 123.02 | 116.44 | 121.38 | 84.99 | 63.30 | 43.28 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 08:16:07 · For reference only, not investment advice and not tailored to your situation.